| 1 |
Wiley SR， Schooley K， S molak PJ， et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity， 1995，3（6）：673-682.
|
| 2 |
宁巍巍，白咸勇. TRAIL 及其受体与肿瘤治疗. 四川解剖学杂志， 2009，17（3）：38-40.
|
| 3 |
Kim K， Fisher MJ， Xu SQ， et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res， 2000，6（2）：335-346.
|
| 4 |
Yoldas B， Ozer C， Ozen O， et al. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck， 2011，33（9）：1278-1284.
|
| 5 |
Srivastava RK. TRAIL/Apo-2L： mechanisms and clinical applications in cancer. Neoplasia， 2001，3（6）：535-546.
|
| 6 |
高显峰，王广义，吕国悦，等. 胰腺癌细胞对TRAIL 耐药机制的研究进展. 吉林医学， 2010，31（5）：665-666.
|
| 7 |
严青春，熊小亮，俞薇薇，等. NF-κB 的活性对TRAIL 诱导肿瘤凋亡的影响研究进展. 肿瘤防治研究， 2010，37（2）：239-241.
|
| 8 |
Mendoza FJ， Ishdorj G， Hu X， et al. Death receptor-4（DR4）expression is regulated by transcription factor NF-kappaB in response to etoposide treatment.Apoptosis，2008，13（6）：756-770.
|
| 9 |
陈淑珍. 靶向TRAIL 受体的抗肿瘤研究进展. 药学学报，2009，44（12）：1336-1342.
|
| 10 |
Ren X， Xu Z， Myers JN， et al. Bypass NFkappaB-mediated survival pathways by TRAIL and Smac. Cancer Biol Ther，2007，6（7）：1031-1035.
|
| 11 |
Horak P， Pils D， Haller G， et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 （DR4） to TRAIL resistance and ovarian cancer. Mol Cancer Res， 2005，3（6）：335-343.
|
| 12 |
McCarthy MM， Sznol M， DiVito KA， et al. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res， 2005，11（14）：5188-5194.
|
| 13 |
Shivapurkar N， Toyooka S， Toyooka KO， et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer， 2004，109（5）：786-792.
|
| 14 |
Jo M， Kim TH， Seol DW， et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosisinducing ligand. Nat Med， 2000，6（5）：564-567.
|
| 15 |
Ichikawa K， Liu W， Zhao L， et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med， 2001，7（8）：954-960.
|
| 16 |
Wu F， Hu Y， Long J， et al. Cytotoxicity and radiosensitization effect of TRA-8 on radioresisitant human larynx squamous carcinoma cells. Oncol Rep， 2009，21（2）：461-465.
|
| 17 |
Estes JM， Oliver PG， Straughn JM Jr， et al. Efficacy of antideath receptor 5 （DR5） antibody （TRA-8） against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol， 2007，105（2）：291-298.
|
| 18 |
Bevis KS， McNally LR， Sellers JC， et al. Anti-tumor activity of an anti-DR5 monoclonal antibody， TRA-8， in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol， 2011，121（1）：193-199.
|
| 19 |
Herbst RS， Eckhardt SG， Kurzrock R， et al. Phase Ⅰdoseescalation study of recombinant human Apo2L/TRAIL， a dual proapoptotic receptor agonist， in patients with advanced cancer.J Clin Oncol， 2010，28（17）：2839-2846.
|
| 20 |
Trarbach T， Moehler M， Heinemann V， et al. Phase Ⅱtrial of mapatumumab， a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosisinducing ligand receptor-1 （TRAIL-R1）， in patients with refractory colorectal cancer. Br J Cancer， 2010，102（3）：506-512.
|
| 21 |
齐荣，蔡莹，李兵华，等. 腺相关病毒携带hTERT 启动子调控的TRAIL 基因特异性杀伤肿瘤细胞. 癌症， 2008，27（10）：1026-1033.
|
| 22 |
Zhang Y， Ma H， Zhang J， et al. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci， 2008，82（23-24）：1154-1161.
|
| 23 |
Jiang M， Liu Z， Xiang Y， et al. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer， 2011，11：54.
|
| 24 |
Seki N， Toh U， Sayers TJ， et al. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther， 2010，9（6）：1842-1851.
|
| 25 |
Lashinger LM， Zhu K， Williams SA， et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res， 2005，65（11）：4902-4908.
|
| 26 |
Nikrad M， Johnson T， Puthalalath H， et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther， 2005，4（3）：443-449.
|
| 27 |
Koschny R， Holland H， Sykora J， et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades Ⅰto Ⅳfor tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res， 2007，13（11）：3403-3412.
|
| 28 |
Voortman J， Resende TP， Abou El Hassan MA， et al. TRAIL therapy in non-small cell lung cancer cells： sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther， 2007，6（7）：2103-2112.
|
| 29 |
Koschny R， Ganten TM， Sykora J， et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancerspecific apoptosis within a therapeutic window. Hepatology，2007，45（3）：649-658.
|
| 30 |
Wiezorek J， Holland P， Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res， 2010，16（6）：1701-1708.
|
| 31 |
Shim SH， Lee CT， Hun Hah J， et al. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck aquamous cell carcinoma. Cancer Sci， 2010，101（2）：482-487.
|
| 32 |
Elord HA， Fan S， Muller S， et al. Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.PLoS One， 2010，5（8）：e12178.
|
| 33 |
Yoldas B， Ozer C， Ozen O， et al. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck， 2011，33（9）：1278-1284.
|